UM-IHC Capabilities and Services
The University of Maryland Institute for Health Computing (UM-IHC) is dedicated to fostering direct and collaborative partnerships with industry leaders to accelerate innovation in health and technology. The UM-IHC brings deep expertise and cutting-edge resources to support projects that deliver meaningful, measurable outcomes. Through these collaborations, UM-IHC works to bridge research and real-world applications, driving progress across multiple domains.
Select Engagement Areas Include:
- AI Model Building – Designing and training advanced artificial intelligence models tailored to specific industry needs.
- AI Model Test and Evaluation – Rigorous validation and performance assessment to ensure reliability and compliance.
- Clinical Trial Support – Data-driven insights and infrastructure to optimize trial design and execution.
- Software Development – Custom solutions that integrate seamlessly with healthcare and research workflows.
- 3D Model Development – High-fidelity modeling for visualization, simulation, and precision medicine applications.
- Predictive Public Health Support – Leveraging analytics to anticipate trends and inform proactive interventions.
- Therapeutic Target Discovery Support – Identifying novel targets to accelerate drug development pipelines.
- Omics Analysis and Interpretation – Comprehensive analysis of genomic, proteomic, and metabolomic data for actionable insights.
IHC Key Capabilities
Research & Discovery
- Clinical expertise & computational expertise
- Bioinformatics
- AI/ML for drug discovery and target identification, validation
- Access to clinical databases and ‘omics data
- Drug design optimization
- Collaborative research platforms
Clinical Development
- Clinical trial design and management (incl. pragmatic, adaptive)
- Patient recruitment and engagement
- Cohort discovery, cohort enhancement (responders vs. non-responders, digital twins)
- Biostatistics and clinical data analysis including data analytics for efficacy/safety profiling
Health Economics & Outcomes Research
- Advanced computation/tech resources
- Clinical algorithm development
- Risk stratification
- Clinical decision support
- Access to EHR and claims databases
Market/Payor Access
- Trial design tailored to payor metrics (e.g. 2-year ROI on new drugs)
- Pragmatic, adaptive, cluster randomized, etc. trials in post-market space
- Testing of non-drug interventions
- Stakeholder engagement, education (payers, providers, patients)
Collaborative Examples
Neurava, a Maryland-based company, has created a device for characterizing physiological responses to epileptic seizures. This digital health technology has demonstrated significant improvement in accuracy and sensitivity over the current standard of care. In preparation for a new round of investment to support wider clinical testing, the company needed data and analytical expertise to define their technology’s role in epilepsy care and the value of the device to patients and payors. The UM-IHC’s team of clinical informaticists, biostatisticians, programmers, health economists, and clinicians partnered with Neurava to quantify the impact of the company’s device on clinical outcomes and resource utilization, arming the founders with key data points to de-risk investment.
With a US headquarters in Gaithersburg, AstraZeneca (AZ) is a flagship of the Maryland life sciences ecosystem. AZ and the University of Maryland share a vision for a State of Maryland where every resident has equitable access to evidence-based cancer screening services and equal opportunity to contribute to the development of newer approaches for early detection and interception of cancer. In a planned project spanning five years, the company has partnered with the University of Maryland Greenebaum Comprehensive Cancer Center and is working with UM-IHC to enact a Maryland-wide early lung cancer detection program, strengthening and expanding the infrastructure for lung cancer screening and tobacco treatment across the state.